Author:
Katunina E. A.,Titova N. V.,Bezdol’nyi Yu. N.,Shikkerimov R. K.,Gasanov M. G.,Burd S. G.,Lebedeva A. V.,Boiko A. N.
Publisher
Springer Science and Business Media LLC
Reference58 articles.
1. R. S. Schwab, L. V. Amador, and J. Y. Lettvin, “Apomorphine in Parkinson’s disease,” Trans. Am. Neurol. Assoc., 76, 251–253 (1951).
2. A. Carlsson, M. Lindqvist, and T. Magnusson, “3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists,” Nature, 180, 1200 (1957).
3. M. D. Yahr, R. C. Duvoisin, M. J. Schear, et al., “Treatment of parkinsonism with levodopa,” Arch. Neurol., 21, 343–354 (1969).
4. G. C. Cotzias, P. S. Papavasiliou, C. Fehling, et al., “Similarities between neurologic effects of L-dopa and apomorphine,” New Eng. J. Med., 282, 31–33 (1970).
5. D. B. Calne, P. F. Teychenne, L. E. Claveria, et al., “Bromocriptine in parkinsonism,” Br. Med. J., 4, 442–444 (1974).